Comparative Pharmacology
Head-to-head clinical analysis: FURALAN versus UREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FURALAN versus UREX.
FURALAN vs UREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
Urex (methenamine hippurate) is hydrolyzed in acidic urine to formaldehyde and ammonia. Formaldehyde denatures bacterial proteins and nucleic acids, exerting a nonspecific bactericidal effect. The hippuric acid component maintains urinary acidity.
20 mg orally three times daily for 7 days.
100 mg orally twice daily for 3 days (uncomplicated UTI) or 100 mg orally once daily for 5 days (prophylaxis).
None Documented
None Documented
Terminal elimination half-life is 8–12 hours in adults with normal renal function; this supports twice-daily dosing. In patients with creatinine clearance <30 mL/min, half-life may be prolonged to 20–30 hours, requiring dose adjustment.
Terminal elimination half-life is 14-18 hours in patients with normal renal function. In renal impairment, half-life is significantly prolonged (up to 40 hours in severe impairment), necessitating dose adjustment.
Approximately 65–70% of an administered dose is excreted unchanged via renal glomerular filtration and tubular secretion; about 10–15% appears in bile as parent drug or glucuronide conjugate; up to 20% is eliminated in feces via unabsorbed fraction or biliary elimination.
Primarily renal: approximately 60-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal elimination accounts for <5%.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective